Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Two-Seventy-One Patent Blog
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: Two-Seventy-One Patent BlogIs The CAFC Pro-Patent? Maybe Not, Claims Study
By Peter Zura
Manasseh Zechariah, economist and assistant professor at Johnson & Wales University College of Business, decided to take groups of decisions from the CAFC, and run variables related to those decisions through different theoretical models to see what came out. Here are some highlights from the study:
? Cases that gets litigated at the trial court which were brought by the patentee are more likely to be decided in favor of the infringer on appeal, as opposed to cases brought to trial by the infringer (i.e., declaratory judgments). Also, a case is likely to be lost at the appeals court by the litigant who brought the case to trial in the first place. However, Zechariah notes that the study does not take into account cases that have not gone through trial (e.g., summary judgment).
? A pro-patent decision by a lower court is more likely to be decided pro-patent by the CAFC if it is appealed. Similarly, an anti-patent decision by a lower court is more likely to be decided anti-patent by the CAFC.
? Overall, the CAFC is likely to rule anti-patent relative to the trial courts on average, but different technology classes of patents are treated differently. While chemical, mechanical and computer patents are more likely to receive an anti-patent ruling, the CAFC has been mostly pro-patent for drug patents.
? Republican appointed judges are more pro-patent than democratic judges.
? In general, patent cases are not likely to be appealed once they have gone through the trial stage. Chemical, electrical and drug patents have higher rates of appeal, but computer patents are less likely to be appealed.
From Zechariah's abstract:
The enforcement of patent rights affects the scope of the monopoly rights provided by them and hence the incentives they provide. Greater likelihood of a pro-patent decision by the enforcement mechanism provides a larger scope of monopoly rights. I investigate the likelihood of a pro-patent decision by the Court of Appeals for the Federal Circuit in patent cases to see how it varies with characteristics of the patent, the litigants and the litigation itself. This model corrects for the fact that not all patent cases get appealed after trial by incorporating a selection model for the appeal of cases. I also incorporate the litigants? uncertainty about appealing a case using a heteroscedastic selection model. I estimate the model using simulated maximum likelihood and use the GHK simulation method. Results show that overall the Court of Appeals for the Federal Circuit is an anti-patent court. However, significant differences exist between different classes of patents with drug patents being more likely to be decided pro-patent than software patents. The Court of Appeals for the Federal Circuit is found to defer to the decisions of the lower court. We also see an increased likelihood of a pro-patent decision by the appeals court with an increase in the proportion of republican judges on the bench.
Read "An Empirical Analysis of the Adjudication of Patent Cases by the Court of Appeals for the Federal Circuit" (link)
Full post as published by Two-Seventy-One Patent Blog on August 07, 2009 (boomark / email).
Paxil Lawsuit
Paxil Claims, Lawsuits, and Injuries
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
False Claims
Attorney Robert Arledge ordered to pay $5.8 million after making false Fen Phen settlement claims.
Procrit
Associated with Death in Stroke Study
Xigris
Study Prompts FDA Safety Review

CAFC Rejects Patent on Invention to Overcome the Second Law of Thermodynamics
CAFC Theory of First-Sale and Patent Exhaustion Gets Cert.
In Re Bilski En Banc Oral Arguments.
Heuft: CAFC rules on infectious prosecution disclaimers
CAFC Applies Lilly to Invalidate Carnegie Mellons Plasmid Claims
In re Swanson: CAFC Allows Reexamination Based on Reference Previously Considered by PTO and Courts







